US20160022703A1 - Composition for Inhalation - Google Patents

Composition for Inhalation Download PDF

Info

Publication number
US20160022703A1
US20160022703A1 US14/635,550 US201514635550A US2016022703A1 US 20160022703 A1 US20160022703 A1 US 20160022703A1 US 201514635550 A US201514635550 A US 201514635550A US 2016022703 A1 US2016022703 A1 US 2016022703A1
Authority
US
United States
Prior art keywords
pvp
peg
budesonide
formoterol
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/635,550
Inventor
Nayna Govind
Maria Marlow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20286853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20160022703(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to US14/635,550 priority Critical patent/US20160022703A1/en
Publication of US20160022703A1 publication Critical patent/US20160022703A1/en
Priority to US15/427,425 priority patent/US10166247B2/en
Priority to US16/108,368 priority patent/US20190216828A1/en
Priority to US16/832,590 priority patent/US11311558B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Definitions

  • the present invention relates to a formulation comprising formoterol and budesonide for use in the treatment of inflammatory conditions/disorders, especially respiratory diseases such as asthma, COPD and rhinitis.
  • Stability is one of the most important factors which determines whether a compound or a mixture of compounds can be developed into a therapeutically useful pharmaceutical product.
  • a pharmaceutical composition comprising formoterol, budesonide, HFA 227 (1,1,1,2,3,3,3-heptafluoropropane), PVP and PEG characterised in that the PVP is present from about 0.0005 to about 0.03% w/w and the PEG is present from about 0.05 to about 0.35% w/w.
  • the PVP is present in an amount of 0.001% w/w.
  • the PVP is PVP K25 (PVP having a nominal K-value of 25).
  • the PEG is present in an amount of 0.3% w/w.
  • the PEG is PEG 1000 (PEG having an average molecular weight of 1000 Daltons).
  • concentrations of formoterol/budesonide are such that the formulation delivers formoterol/budesonide at 4.5/40 mcg, 4.5/80 mcg, 4.5/160 mcg or 4.5/320mcg per actuation.
  • the formoterol can be in the form of a mixture of enantiomers.
  • the formoterol is in the form of a single enantiomer, preferably the R, R enantiomer.
  • the formoterol can be in the form of the free base, salt or solvate, or a solvate of a salt, preferably the formoterol is in the form of its fumarate dihydrate salt.
  • physiologically salts include chloride, bromide, sulphate, phosphate, maleate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, benzenesulphonate, ascorbate, acetate, succinate, lactate, glutarate, gluconate, tricaballate, hydroxynapaphthalenecarboxylate or oleate.
  • the second active ingredient is budesonide, including epimers, esters, salts and solvates thereof. More preferably the second active ingredient is budesonide or an epimer thereof, such as the 22R-epimer of budesonide.
  • compositions according to the invention can be used for the treatment or prophylaxis of a respiratory disorder, in particular the treatment or prophylaxis of asthma, rhinitis or COPD.
  • the invention provides a method of treating a respiratory disorder, in particular asthma, rhinitis or COPD, in a mammal, which comprises administering to a patient a pharmaceutical composition as herein defined.
  • a respiratory disorder in particular asthma, rhinitis or COPD
  • compositions of the invention can be inhaled from any suitable MDI device. Doses will be dependent on the severity of the disease and the type of patient, but are preferably 4.5/80 mcg or 4.5/160 mcg per actuation as defined above.
  • the concentration of PVP (0.001% w/w) used in this formulation has been found to give consistently stable formulations over the required dose range, incorporating a wide range of concentrations of the active components, and at a much lower concentration than indicated in the prior art.
  • FIG. 1 is a schematic drawing of an Optical Suspension Characterisation (OSCAR) set-up.
  • OSCAR Optical Suspension Characterisation
  • FIGS. 2-3 are graphs showing the averages of OSCAR data (lower sensor) for formulations in HFA 227 containing 4.5 ⁇ g formoterol; 0.3% w/w PEG 1000; 0.0001%-0.05% w/w PVP K25; and 160 ⁇ g budesonide ( FIG. 2 ) or 80 ⁇ g budesonide ( FIG. 3 ).
  • FIGS. 4-6 are graphs showing the averages of Turbiscan data for formulations in HFA 227 containing 4.5 ⁇ g formoterol; 0.3% w/w PEG 1000; 0.0001%-0.05% w/w PVP K25; and 160 ⁇ g budesonide ( FIG. 4 ), 80 ⁇ g budesonide ( FIG. 5 ), or 40 ⁇ g budesonide ( FIG. 6 ).
  • FIG. 7 is a graph showing the effect of PEG 1000 concentration on stem return force for formulations containing 4.5 ⁇ g formoterol; 160 ⁇ g budesonide; and 0.1%, 0.3%, or 0.5% w/w PEG 1000.
  • FIG. 8 is a graph showing the averages of Turbiscan data for formulations in HFA 227 containing 80 ⁇ g budesonide; 4.5 ⁇ g formoterol; 0.0001% PVP K25; and 0.005%-0.5% w/w PEG 1000.
  • FIGS. 9-11 are a series of digital photographs, taken after standing times of 0 seconds ( FIG. 9 ), 30 seconds ( FIGS. 10 ), and 60 seconds ( FIG. 11 ), of suspensions in HFA 227 containing budesonide (160 ⁇ g/actuation); formoterol (4.5 ⁇ g/actuation); 0.3% PEG 1000; and PVP K25 at 0.0001%, 0.0005%, 0.001%, 0.01%, 0.03%, and 0.05% w/w.
  • FIGS. 12-14 are a series of digital photographs, taken after standing times of 0 seconds ( FIG. 12 ), 30 seconds ( FIGS. 13 ), and 60 seconds ( FIG. 14 ), of suspensions in HFA 227 containing budesonide (80 ⁇ g/actuation); formoterol (4.5 ⁇ g/actuation); 0.3% PEG 1000; and PVP K25 at 0.0001%, 0.0005%, 0.001%, 0.01%, 0.03%, and 0.05% w/w.
  • FIGS. 15-16 are digital photographs, taken after standing times of 0 minutes ( FIG. 15 ) and 10 minutes ( FIG. 16 ), of suspensions in HFA 227 containing budesonide (80 ⁇ g/actuation); formoterol (4.5 ⁇ g/actuation); 0.001% PVP K25; and PEG 1000 at 0.005, 0.05, 0.35, and 0.5% w/w.
  • OSCAR Optical suspension characterisation
  • TURBISCAN Optical suspension characterisation
  • Optical Suspension Characterisation (OSCAR) equipment is custom designed for the rapid and reproducible semi-quantification of metered dose inhaler suspension characteristics.
  • the OSCAR equipment utilises changes in light transmission with time, to characterise a pre-agitated suspension formulation (a schematic diagram of the equipment is shown in FIG. 1 ).
  • the equipment consists of a twin headed test assembly. The head on the left side of the equipment is used with dilute suspensions and the right for concentrated suspensions.
  • the selector switch mounted between the two test heads is used to alternate concentration choice.
  • the output from the selected test head is directed to the equipment mounted voltage display and to the computer for data logging.
  • the analogue signals from photodetectors are digitised and the values collected in data files, these are then processed using a suitable software package.
  • the upper and lower photodetectors are height adjustable and a position readout display is provided to indicate the set height for each test run.
  • the Reagecon Turbidity standards (2500-4000 NTU) are used to calibrate the sensitivity of the OSCAR equipment.
  • the 3000 NTU turbidity calibration standard is used as a standard calibration check.
  • any of the turbidity standards can be used to adjust the sensitivity of the probes to a specific voltage appropriate to the formulation.
  • Turbiscan MA 2000 is a concentrated dispersion and emulsion stability and instability analyser, or a vertical scan macroscopic analyser. It consists of a reading head moving along a flat-bottomed, 5 ml cylindrical glass cell, which takes readings of transmitted and backscattered light every 40 ⁇ m on a maximum sample height of 80 mm. The scan can be repeated with a programmable frequency to obtain a macroscopic fingerprint of the sample.
  • the profile obtained characterises the samples homogeneity, concentration and mean particle diameter. It allows for quantification of the physical processes the sample is undergoing. As well as detecting destabilisation, Turbiscan allows comparison of, for example, the sedimentation rate of different suspensions.
  • Turbiscan may be used in several modes, e.g., transmitted or backscattering modes. Turbiscan has been used here in these examples to measure the transmitted light as a function of time.
  • Dispersion instability is the result of two physical processes: a) particle size increases as a result of the formation of aggregates, due to flocculation; and b) particle migration resulting in creaming or sedimentation.
  • a product is stable (i.e., no flocculation, creaming or sedimentation)
  • the transmitted and backscattered light will remain constant i.e. scans of these will show a constant level profile. If the product undergoes changes in particle size, variations in the transmitted/backscattered light show as change in the direction of the scan from horizontal or steady state profile.
  • a cell capable of handling pressurised samples is required. Such a cell was used for the evaluations of these HFA formulations. The scans were performed in the AUTO mode.
  • the % transmission averages shown in the figure (see later) were taken from a zone around the middle of the suspension sample.
  • Formulations containing formoterol fumarate dihydrate, budesonide, 0.001% w/w PVP K25 and either 0.1% w/w or 0.3% PEG 1000 in HFA-227 were prepared in polyethylene terephthalate (PET) bottles crimped with a continuous valve.
  • PET polyethylene terephthalate
  • the formoterol fumarate dihydrate concentration remained constant at 0.09mg/ml (equivalent to 4.5 mcg formoterol fumarate dihydrate per actuation) and the budesonide concentration varied between approximately 1 mg/ml to 8 mg/ml (equivalent to 40 mcg to 320 mcg per actuation).
  • OSCAR analysis of these formulations gave relatively low light transmittance values at the lower sensor, which is indicative of stable suspensions with low flocculation characteristics. Early indications were that the 0.001% w/w PVP with 0.3% PEG 1000 would give the best suspension.
  • OSCAR, Turbiscan and photographic methods were used to evaluate the formulations. OSCAR and Turbiscan techniques have been described earlier. Samples with varying concentrations of PVP were analysed to determine suspension stability over time.
  • FIGS. 9 , 10 and 11 show Budesonide 160 ⁇ g/shot, Formoterol 4.5 ⁇ g/shot with various PVP K25 concentrations and 0.3% PEG 1000 at 0, 30, and 60 seconds standing time.
  • FIGS. 12 , 13 and 14 shows Budesonide 80 ⁇ g/shot, Formoterol 4.5 ⁇ g/shot with various PVP K25 concentrations and 0.3% PEG 1000 at 0, 30, and 60 seconds standing time.
  • Photographs were taken of all doses (320 ⁇ g/4.5 ⁇ g to 40 ⁇ g/4.5 ⁇ g) at 0, 15, 30, 60, 90 seconds, and 2, 5 and 10 minutes. As this produced too many photographs to reproduce here, a chart has been constructed to give a representation of the degree of dispersion over time.
  • the sample was fully suspended, the sample was rated 0, i.e., at 0 minutes they were fully dispersed. From there, the samples have been rated in increments of 1-5 at 20% intervals to express the degree of dispersion: i.e., 0 was fully suspended and 5 fully creamed. This allows some comparison across the whole dose range and PVP concentration range used.
  • FIG. 2 shows the average OSCAR transmission readings (lower sensor only) for various concentrations of PVP K25.
  • a low transmission reading indicates that the suspension is dispersed, preventing light being transmitted. Hence, it can be seen that the lowest line is the most stable formulation. This is the 0.001% PVP sample.
  • FIGS. 5 and 6 show that the suspension with 0.001% w/w PVP is the most stable (bottom bold line) with the lowest % transmission.
  • FURTHER EVALUATION Determination of the optimum PEG 1000 concentration.
  • Force to fire testing was performed using the Lloyd LRX testing machine.
  • the pMDI unit to be tested was placed valve down in a can holder on the lower platform of the unit.
  • the upper crosshead was then moved to just above the base of the can.
  • Can actuations were performed using a standard protocol.
  • force data is captured by means of the load cell located at the top of the upper crosshead. This program was designed to output the return force at 0.5 mm stem return as this is the point at which the metering chamber is considered to refill.
  • a low return force is indicative of high friction and potential sticking problems. It also suggests there may be a problem with low actuation weights as the propellant enters the metering chamber more slowly and has time to vaporise. Force to fire testing was performed at preset actuations.
  • FIG. 7 shows the effect of PEG 1000 concentration on stem return force for the 4.5/160 ⁇ g formoterol/budesonide formulation
  • the Turbiscan data shows that there is little difference between the stability of suspensions made with varying levels of PEG 1000 except for the 0.005% w/w level which was unsatisfactory.
  • FIGS. 15 and 16 show Budesonide 80 ⁇ g/shot, Formoterol 4.5 ⁇ g/shot with 0.001% PVP K25 and various concentrations of PEG 1000 at 0 (1) and 10 minutes (2) standing time.
  • Fine particle fraction (% cumulative undersize for 4.7 ⁇ m cut-off) Product strength 25° C./ 25° C./ ( ⁇ g) 60% RH 60% RH (FFD/budesonide) Drug Initial 6 months 12 months 4.5/80 Budesonide 51.3 52.8 62.0 FFD 55.4 53.5 59.7 4.5/160 Budesonide 50.0 48.8 47.0 FFD 54.2 52.1 51.3
  • Fine particle fraction (% cumulative undersize for 4.7 ⁇ m cut-off) Product strength 25° C./ 25° C./ ( ⁇ g) 60% RH 60% RH (FFD/budesonide) Drug Initial 6 months 12 months 4.5/80 Budesonide 55.8 50.6 51.3 FFD 64.2 57.6 58.7 4.5/160 Budesonide 48.7 50.2 52.3 FFD 55.6 59.1 61.2

Abstract

The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.

Description

    TECHNICAL FIELD
  • The present invention relates to a formulation comprising formoterol and budesonide for use in the treatment of inflammatory conditions/disorders, especially respiratory diseases such as asthma, COPD and rhinitis.
    • BACKGROUND
  • Stability is one of the most important factors which determines whether a compound or a mixture of compounds can be developed into a therapeutically useful pharmaceutical product.
  • Combinations of formoterol and budesonide are known in the art, see for example WO 93/11773 discloses such a combination that is now marketed as Symbicort® in a dry powder inhaler. There are a variety of other inhalers by which a respiratory product can be administered, such as pressurised metered dose inhalers (pMDI's). Formulations for pMDI's may require certain excipients as disclosed in WO 93/05765.
  • It has now been found that certain HFA formulations comprising formoterol and budesonide together with polyvinylpyrrolidone (PVP) and polyethylene glycol (PEG) exhibit excellent physical suspension stability.
    • DESCRIPTION
  • In accordance with the present invention, there is provided a pharmaceutical composition comprising formoterol, budesonide, HFA 227 (1,1,1,2,3,3,3-heptafluoropropane), PVP and PEG characterised in that the PVP is present from about 0.0005 to about 0.03% w/w and the PEG is present from about 0.05 to about 0.35% w/w.
  • Preferably the PVP is present in an amount of 0.001% w/w. Preferably the PVP is PVP K25 (PVP having a nominal K-value of 25).
  • Preferably the PEG is present in an amount of 0.3% w/w. Preferably the PEG is PEG 1000 (PEG having an average molecular weight of 1000 Daltons).
  • Preferably the concentrations of formoterol/budesonide are such that the formulation delivers formoterol/budesonide at 4.5/40 mcg, 4.5/80 mcg, 4.5/160 mcg or 4.5/320mcg per actuation.
  • The formoterol can be in the form of a mixture of enantiomers. Preferably the formoterol is in the form of a single enantiomer, preferably the R, R enantiomer. The formoterol can be in the form of the free base, salt or solvate, or a solvate of a salt, preferably the formoterol is in the form of its fumarate dihydrate salt. Other suitable physiologically salts that can be used include chloride, bromide, sulphate, phosphate, maleate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, benzenesulphonate, ascorbate, acetate, succinate, lactate, glutarate, gluconate, tricaballate, hydroxynapaphthalenecarboxylate or oleate.
  • Preferably the second active ingredient is budesonide, including epimers, esters, salts and solvates thereof. More preferably the second active ingredient is budesonide or an epimer thereof, such as the 22R-epimer of budesonide.
  • The pharmaceutical compositions according to the invention can be used for the treatment or prophylaxis of a respiratory disorder, in particular the treatment or prophylaxis of asthma, rhinitis or COPD.
  • In a further aspect the invention provides a method of treating a respiratory disorder, in particular asthma, rhinitis or COPD, in a mammal, which comprises administering to a patient a pharmaceutical composition as herein defined.
  • The compositions of the invention can be inhaled from any suitable MDI device. Doses will be dependent on the severity of the disease and the type of patient, but are preferably 4.5/80 mcg or 4.5/160 mcg per actuation as defined above.
  • The concentration of PVP (0.001% w/w) used in this formulation has been found to give consistently stable formulations over the required dose range, incorporating a wide range of concentrations of the active components, and at a much lower concentration than indicated in the prior art.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a schematic drawing of an Optical Suspension Characterisation (OSCAR) set-up.
  • FIGS. 2-3 are graphs showing the averages of OSCAR data (lower sensor) for formulations in HFA 227 containing 4.5 μg formoterol; 0.3% w/w PEG 1000; 0.0001%-0.05% w/w PVP K25; and 160 μg budesonide (FIG. 2) or 80 μg budesonide (FIG. 3).
  • FIGS. 4-6 are graphs showing the averages of Turbiscan data for formulations in HFA 227 containing 4.5 μg formoterol; 0.3% w/w PEG 1000; 0.0001%-0.05% w/w PVP K25; and 160 μg budesonide (FIG. 4), 80 μg budesonide (FIG. 5), or 40 μg budesonide (FIG. 6).
  • FIG. 7 is a graph showing the effect of PEG 1000 concentration on stem return force for formulations containing 4.5 μg formoterol; 160 μg budesonide; and 0.1%, 0.3%, or 0.5% w/w PEG 1000.
  • FIG. 8 is a graph showing the averages of Turbiscan data for formulations in HFA 227 containing 80 μg budesonide; 4.5 μg formoterol; 0.0001% PVP K25; and 0.005%-0.5% w/w PEG 1000.
  • FIGS. 9-11 are a series of digital photographs, taken after standing times of 0 seconds (FIG. 9), 30 seconds (FIGS. 10), and 60 seconds (FIG. 11), of suspensions in HFA 227 containing budesonide (160 μg/actuation); formoterol (4.5 μg/actuation); 0.3% PEG 1000; and PVP K25 at 0.0001%, 0.0005%, 0.001%, 0.01%, 0.03%, and 0.05% w/w.
  • FIGS. 12-14 are a series of digital photographs, taken after standing times of 0 seconds (FIG. 12), 30 seconds (FIGS. 13), and 60 seconds (FIG. 14), of suspensions in HFA 227 containing budesonide (80 μg/actuation); formoterol (4.5 μg/actuation); 0.3% PEG 1000; and PVP K25 at 0.0001%, 0.0005%, 0.001%, 0.01%, 0.03%, and 0.05% w/w.
  • FIGS. 15-16 are digital photographs, taken after standing times of 0 minutes (FIG. 15) and 10 minutes (FIG. 16), of suspensions in HFA 227 containing budesonide (80 μg/actuation); formoterol (4.5 μg/actuation); 0.001% PVP K25; and PEG 1000 at 0.005, 0.05, 0.35, and 0.5% w/w.
    •
  • The invention is illustrated by the following examples.
    • EXPERIMENTAL SECTION
  • Two methods can be used to evaluate physical suspension stability: Optical suspension characterisation (OSCAR), and TURBISCAN. Both methods are used to semi-quantify sedimentation/creaming rates. OSCAR measurements are performed using the PET bottles directly. For TURBISCAN analysis, the suspensions are transferred to custom designed pressure cells for measurement of light transmittance and backscattering.
  • Methodology
  • OSCAR
  • Optical Suspension Characterisation (OSCAR) equipment is custom designed for the rapid and reproducible semi-quantification of metered dose inhaler suspension characteristics.
  • The OSCAR equipment utilises changes in light transmission with time, to characterise a pre-agitated suspension formulation (a schematic diagram of the equipment is shown in FIG. 1). The equipment consists of a twin headed test assembly. The head on the left side of the equipment is used with dilute suspensions and the right for concentrated suspensions. The selector switch mounted between the two test heads is used to alternate concentration choice. The output from the selected test head is directed to the equipment mounted voltage display and to the computer for data logging. The analogue signals from photodetectors are digitised and the values collected in data files, these are then processed using a suitable software package. There are two equipment mounted voltage displays, one each for the upper and lower photodetectors. The upper and lower photodetectors are height adjustable and a position readout display is provided to indicate the set height for each test run.
  • The Reagecon Turbidity standards (2500-4000 NTU) are used to calibrate the sensitivity of the OSCAR equipment. In this case, the 3000 NTU turbidity calibration standard is used as a standard calibration check. However any of the turbidity standards can be used to adjust the sensitivity of the probes to a specific voltage appropriate to the formulation.
  • Samples for test on the OSCAR equipment are presented in PET bottles crimped with non-metering valves.
  • For background information and prior art for this method refer to papers from Drug Delivery to the Lungs IX, 1997, Method Development of the OSCAR technique for the characterization of metered dose inhaler formulations, Authors N. Govind, P. Lambert And Drug delivery to the Lungs VI, 1995, A Rapid Technique for Characterisation of the Suspension Dynamics of metered Dose Inhaler Formulations, Author, P A Jinks (3M Healthcare Ltd)
  • Turbiscan
  • Turbiscan MA 2000 is a concentrated dispersion and emulsion stability and instability analyser, or a vertical scan macroscopic analyser. It consists of a reading head moving along a flat-bottomed, 5 ml cylindrical glass cell, which takes readings of transmitted and backscattered light every 40 μm on a maximum sample height of 80 mm. The scan can be repeated with a programmable frequency to obtain a macroscopic fingerprint of the sample.
  • The reading head uses a pulsed near infrared light source (wavelength=850 nm) and two synchronous detectors:
      • Transmission detector: Picks up light transmitted through the solution in the tube, at 0°
      • Backscattering detector: Receives the light back scattered by the product at 135°.
  • The profile obtained characterises the samples homogeneity, concentration and mean particle diameter. It allows for quantification of the physical processes the sample is undergoing. As well as detecting destabilisation, Turbiscan allows comparison of, for example, the sedimentation rate of different suspensions.
  • Turbiscan may be used in several modes, e.g., transmitted or backscattering modes. Turbiscan has been used here in these examples to measure the transmitted light as a function of time.
  • Dispersion instability is the result of two physical processes: a) particle size increases as a result of the formation of aggregates, due to flocculation; and b) particle migration resulting in creaming or sedimentation. When a product is stable (i.e., no flocculation, creaming or sedimentation), the transmitted and backscattered light will remain constant i.e. scans of these will show a constant level profile. If the product undergoes changes in particle size, variations in the transmitted/backscattered light show as change in the direction of the scan from horizontal or steady state profile.
  • For pressurised systems a cell capable of handling pressurised samples is required. Such a cell was used for the evaluations of these HFA formulations. The scans were performed in the AUTO mode.
  • The % transmission averages shown in the figure (see later) were taken from a zone around the middle of the suspension sample.
  • Initial Evaluation
  • For the initial evaluation, only OSCAR was used.
  • Formulations containing formoterol fumarate dihydrate, budesonide, 0.001% w/w PVP K25 and either 0.1% w/w or 0.3% PEG 1000 in HFA-227 were prepared in polyethylene terephthalate (PET) bottles crimped with a continuous valve. For all formulations, the formoterol fumarate dihydrate concentration remained constant at 0.09mg/ml (equivalent to 4.5 mcg formoterol fumarate dihydrate per actuation) and the budesonide concentration varied between approximately 1 mg/ml to 8 mg/ml (equivalent to 40 mcg to 320 mcg per actuation).
  • Early OSCAR Data for Symbicort pMDI Formulations
  • Transmittance
    (mV)
    Budesonide Formoterol PVP K25 Lower sensor
    dose dose concentration Time PEG concn % w/w
    ex-actuator ex-actuator (% w/w ) seconds 0.1 0.3
     40 μg 4.5 μg 0.001 30 seconds  257
    60 seconds  264
     80 μg 4.5 μg 0.001 30 seconds 202
    60 seconds 240
    0.002 30 seconds 184
    60 seconds 185
    160 μg 4.5 μg 0.001 30 seconds 208  114
    60 seconds 304  191
    0.002 30 seconds 248
    60 seconds 327
    320 μg 4.5 μg 0.001 30 seconds  475
    60 seconds  570
    0.002 30 seconds  930
    60 seconds 1443
  • OSCAR analysis of these formulations gave relatively low light transmittance values at the lower sensor, which is indicative of stable suspensions with low flocculation characteristics. Early indications were that the 0.001% w/w PVP with 0.3% PEG 1000 would give the best suspension.
  • FURTHER EVALUATION: various concentrations of PVP K25 with a constant PEG 1000 concentration of 0.3% w/w.
  • OSCAR, Turbiscan and photographic methods were used to evaluate the formulations. OSCAR and Turbiscan techniques have been described earlier. Samples with varying concentrations of PVP were analysed to determine suspension stability over time.
  • Photographic Analysis
  • For the photographic analysis, samples were prepared in PET bottles and photographed digitally over time, using a black background. These photographs (some of which are shown here) show the behaviour of the suspension over time and allow easy comparison of the effectiveness of the various concentrations of PVP. The concentration of PVP varied from 0.0001 to 0.05% w/w. From left to right on the photographs the concentration of PVP is as follows:
  •
    0.0001 0.0005 0.001 0.01 0.03 0.05
    far left far right
  • Digital Photography of Formulations Showing Degree of Dispersion Over Time
  • FIGS. 9, 10 and 11 show Budesonide 160 μg/shot, Formoterol 4.5 μg/shot with various PVP K25 concentrations and 0.3% PEG 1000 at 0, 30, and 60 seconds standing time.
  • FIGS. 12, 13 and 14 shows Budesonide 80 μg/shot, Formoterol 4.5 μg/shot with various PVP K25 concentrations and 0.3% PEG 1000 at 0, 30, and 60 seconds standing time.
  • Table of Degree of Dispersion of Suspensions Over Time: (All Samples)
  • Photographs were taken of all doses (320 μg/4.5 μg to 40 μg/4.5 μg) at 0, 15, 30, 60, 90 seconds, and 2, 5 and 10 minutes. As this produced too many photographs to reproduce here, a chart has been constructed to give a representation of the degree of dispersion over time.
  • If the sample was fully suspended, the sample was rated 0, i.e., at 0 minutes they were fully dispersed. From there, the samples have been rated in increments of 1-5 at 20% intervals to express the degree of dispersion: i.e., 0 was fully suspended and 5 fully creamed. This allows some comparison across the whole dose range and PVP concentration range used.
  • (Note concentration of Formoterol is 4.5 μg/shot in all the samples)
  • (Samples are all fully dispersed at 0 seconds and therefore all have a score of 0)
  •
    Fully dispersed—0
    More than 80% dispersed, i.e., less than 20% clear liquid present 1
    More than 60% dispersed, i.e., less than 40% clear liquid present 2
    Less than 40% dispersed, i.e., more than 60% clear liquid present 3
    Less than 20% dispersed, i.e., more than 80% clear liquid present 4
    Fully creamed 5
  • TABLE OF DEGREE OF DISPERSION OF
    SUSPENSIONS OVER TIME: ALL SAMPLES
    Dose Time
    μg/shot Sec/ PVP concentration (% w/w)
    Budesonide mins 0.0001 0.0005 0.001 0.01 0.03 0.05
    320 15 2 1 0-1 0-1 0-1 0-1
    30 3 3 2 1-2 2 2
    60 4 4 3-4 2 3 3-4
    90 4 5 5 3 5 5
    2 5 5 4-5 4-5 5 5
    5 5 5 5 5 5 5
    10 5 5 5 5 5 5
    160 15 3 2 0-1 0-1 2 2
    30 3 2 1 1 2 2
    60 5 4 1 2 4 5
    90 5 5 1 2 5 5
    2 5 5 1 2 5 5
    5 5 5 2 4 5 5
    10 5 5 2 4 5 5
     80 15 2 1 0 0 1 1
    30 3 2 1 1 2 2
    60 4 2 1 1-2 3 3
    90 5 3 1-2 1-2 4 3
    2 5 3-4 1 1 5 4
    5 5 4 2 2 5 5
    10 5 5 3 3 5 5
     40 15 1 1 0 0 1 2
    30 2 1 1 2 2 3
    60 1-2 1 1 2 2 3
    90 1-2 1-2 1-2 2 2-3 4
    2 2 2 2 3 4 5
    5 3 2 2 3 4 5
    10 4-5 3 2 4 5 5
  • Suspensions considered excellent are highlighted in bold.
  • It can be seen that the formulations with 0.001% w/w PVP gave the best suspension stability overall.
  • OSCAR Data (Graphs of Light Transmission Versus Time)
  • FIG. 2 shows the average OSCAR transmission readings (lower sensor only) for various concentrations of PVP K25. A low transmission reading indicates that the suspension is dispersed, preventing light being transmitted. Hence, it can be seen that the lowest line is the most stable formulation. This is the 0.001% PVP sample.
  • In FIG. 3, the bottom line, again with low transmission readings, clearly shows that the formulation containing 0.001% PVP is the most stable.
  • TURBISCAN Data (Graphs of Percentage (%) Light Transmission Versus Time)
  • Data from the Turbiscan can be interpreted in a similar vein to the OSCAR data in that a low percentage (%) transmission indicates the suspension is dispersed. The % transmission averages quoted here were taken from a zone around the middle of the suspension sample. In FIG. 4 the most stable formulation is the lowest line with the lowest % transmission, i.e. the bold black line with 0.001% w/w PVP
  • FIGS. 5 and 6 show that the suspension with 0.001% w/w PVP is the most stable (bottom bold line) with the lowest % transmission.
  • FURTHER EVALUATION: Determination of the optimum PEG 1000 concentration.
  • For this evaluation, photography, turbiscan and force to fire data (valve performance) was used to determine the optimum PEG concentration.
  • METHODOLOGY—Force to fire (return force at 0.5 mm stem return)
  • Force to fire testing was performed using the Lloyd LRX testing machine. The pMDI unit to be tested was placed valve down in a can holder on the lower platform of the unit. The upper crosshead was then moved to just above the base of the can. Can actuations were performed using a standard protocol. During measurement, force data is captured by means of the load cell located at the top of the upper crosshead. This program was designed to output the return force at 0.5 mm stem return as this is the point at which the metering chamber is considered to refill.
  • A low return force is indicative of high friction and potential sticking problems. It also suggests there may be a problem with low actuation weights as the propellant enters the metering chamber more slowly and has time to vaporise. Force to fire testing was performed at preset actuations.
  • Data
  • Force to Fire Data
  • FIG. 7 shows the effect of PEG 1000 concentration on stem return force for the 4.5/160 μg formoterol/budesonide formulation
  • This shows that at 120 actuations, the return force is greater for the 0.3% w/w PEG 1000 concentration than for the other concentrations of 0.5% and 0.1%. In general, the higher the return force the lesser the chance of the valve stem sticking. The above data shows that in this case 0.3% would be preferred.
  • Turbiscan Data
  • The Turbiscan data (FIG. 8) shows that there is little difference between the stability of suspensions made with varying levels of PEG 1000 except for the 0.005% w/w level which was unsatisfactory.
  • Photographic Analysis
  • Digital photographs of suspensions containing Budesonide, Formoterol, HFA 227, 0.001% w/w PVP and varying levels of PEG 1000 show little variation in suspension stability over time (0 seconds to 10 minutes) except for the 0.005% w/w PEG level (in agreement with the Turbiscan data).
  • FIGS. 15 and 16 show Budesonide 80 μg/shot, Formoterol 4.5 μg/shot with 0.001% PVP K25 and various concentrations of PEG 1000 at 0 (1) and 10 minutes (2) standing time.
  • Product Performance Data
  • In addition to the above, product performance data for formulations containing formoterol fumarate dihydrate/budesonide at the following strengths: 4.5/80 mcg per actuation and 4.5/160 mcg per actuation, with 0.001% PVP K25 and either 0.1% or 0.3% PEG 1000, were stable for up to 12 months at 25° C./60% RH.
  • Product Performance Data for Symbicort Formulations Containing 0.001% PVP K25 and 0.1% PEG 1000 in HFA-227
  • Fine particle fraction (% cumulative
    undersize for 4.7 μm cut-off)
    Product strength 25° C./ 25° C./
    (μg) 60% RH 60% RH
    (FFD/budesonide) Drug Initial 6 months 12 months
    4.5/80 Budesonide 51.3 52.8 62.0
    FFD 55.4 53.5 59.7
    4.5/160 Budesonide 50.0 48.8 47.0
    FFD 54.2 52.1 51.3
  • Product Performance Data for Symbicort Formulations Containing 0.001% PVP K25 and 0.3% PEG 1000 in HFA-227
  • Fine particle fraction (% cumulative
    undersize for 4.7 μm cut-off)
    Product strength 25° C./ 25° C./
    (μg) 60% RH 60% RH
    (FFD/budesonide) Drug Initial 6 months 12 months
    4.5/80 Budesonide 55.8 50.6 51.3
    FFD 64.2 57.6 58.7
    4.5/160 Budesonide 48.7 50.2 52.3
    FFD 55.6 59.1 61.2

Claims (12)

1. A pharmaceutical composition comprising formoterol, budesonide, HFA 227, PVP and PEG.
2. A formulation according to claim 1 characterised in that the PVP is present from about 0.0005 to about 0.05% w/w and the PEG is present from about 0.05 to about 0.35% w/w.
3. A pharmaceutical composition according to claim 1 in which the PVP is PVP K25.
4. A pharmaceutical composition according to claim 1 in which the PVP is present in an amount of 0.001% w/w.
5. A pharmaceutical composition according to claim 1 in which the PEG is PEG 1000.
6. A pharmaceutical composition according to claim 1 in which the PEG is present in an amount of 0.3% w/w.
7. A pharmaceutical composition according to claim 1 in which formoterol is in the form of its fumarate dihydrate salt.
8. A pharmaceutical composition according to claim 1 in which the formoterol is in the form of the single R, R-enantiomer.
9. A pharmaceutical composition according to claim 1 in which the second active ingredient is the 22R-epimer of budesonide.
10. A pharmaceutical composition according to claim 1 for use for the treatment or prophylaxis of a respiratory disorder.
11. A pharmaceutical composition according to claim 1 for use for the treatment or prophylaxis of asthma, rhinitis or COPD.
12. A method of treating a respiratory disorder in a mammal which comprises administering to a patient a pharmaceutical composition according to claim 1.
US14/635,550 2002-02-01 2015-03-02 Composition for Inhalation Abandoned US20160022703A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US14/635,550 US20160022703A1 (en) 2002-02-01 2015-03-02 Composition for Inhalation
US15/427,425 US10166247B2 (en) 2002-02-01 2017-02-08 Composition for inhalation
US16/108,368 US20190216828A1 (en) 2002-02-01 2018-08-22 Composition for Inhalation
US16/832,590 US11311558B2 (en) 2002-02-01 2020-03-27 Composition for inhalation

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
SE0200312.7 2002-02-01
SE0200312A SE0200312D0 (en) 2002-02-01 2002-02-01 Novel composition
PCT/SE2003/000156 WO2003063842A1 (en) 2002-02-01 2003-01-29 Composition for inhalation
US10/502,685 US7759328B2 (en) 2002-02-01 2003-01-29 Composition for inhalation
US12/790,196 US8143239B2 (en) 2002-02-01 2010-05-28 Composition for inhalation
US13/411,939 US8575137B2 (en) 2002-02-01 2012-03-05 Composition for inhalation
US14/057,548 US20140286878A1 (en) 2002-02-01 2013-10-18 Composition for inhalation
US14/635,550 US20160022703A1 (en) 2002-02-01 2015-03-02 Composition for Inhalation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/057,548 Continuation US20140286878A1 (en) 2002-02-01 2013-10-18 Composition for inhalation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US201615186665A Continuation 2002-02-01 2016-06-20

Publications (1)

Publication Number Publication Date
US20160022703A1 true US20160022703A1 (en) 2016-01-28

Family

ID=20286853

Family Applications (8)

Application Number Title Priority Date Filing Date
US10/502,685 Expired - Lifetime US7759328B2 (en) 2002-02-01 2003-01-29 Composition for inhalation
US12/790,196 Expired - Fee Related US8143239B2 (en) 2002-02-01 2010-05-28 Composition for inhalation
US13/411,939 Expired - Lifetime US8575137B2 (en) 2002-02-01 2012-03-05 Composition for inhalation
US14/057,548 Abandoned US20140286878A1 (en) 2002-02-01 2013-10-18 Composition for inhalation
US14/635,550 Abandoned US20160022703A1 (en) 2002-02-01 2015-03-02 Composition for Inhalation
US15/427,425 Expired - Lifetime US10166247B2 (en) 2002-02-01 2017-02-08 Composition for inhalation
US16/108,368 Abandoned US20190216828A1 (en) 2002-02-01 2018-08-22 Composition for Inhalation
US16/832,590 Expired - Lifetime US11311558B2 (en) 2002-02-01 2020-03-27 Composition for inhalation

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US10/502,685 Expired - Lifetime US7759328B2 (en) 2002-02-01 2003-01-29 Composition for inhalation
US12/790,196 Expired - Fee Related US8143239B2 (en) 2002-02-01 2010-05-28 Composition for inhalation
US13/411,939 Expired - Lifetime US8575137B2 (en) 2002-02-01 2012-03-05 Composition for inhalation
US14/057,548 Abandoned US20140286878A1 (en) 2002-02-01 2013-10-18 Composition for inhalation

Family Applications After (3)

Application Number Title Priority Date Filing Date
US15/427,425 Expired - Lifetime US10166247B2 (en) 2002-02-01 2017-02-08 Composition for inhalation
US16/108,368 Abandoned US20190216828A1 (en) 2002-02-01 2018-08-22 Composition for Inhalation
US16/832,590 Expired - Lifetime US11311558B2 (en) 2002-02-01 2020-03-27 Composition for inhalation

Country Status (28)

Country Link
US (8) US7759328B2 (en)
EP (2) EP1474117B1 (en)
JP (2) JP2005521663A (en)
KR (2) KR20090125857A (en)
CN (1) CN1287774C (en)
AT (2) ATE423552T1 (en)
AU (1) AU2003206289B2 (en)
BR (1) BR0307193A (en)
CA (1) CA2474479C (en)
CO (1) CO5611098A2 (en)
CY (2) CY1109030T1 (en)
DE (2) DE60332067D1 (en)
DK (2) DK2036549T3 (en)
ES (2) ES2321180T3 (en)
HK (1) HK1126684A1 (en)
IL (1) IL163160A (en)
IS (2) IS7360A (en)
MX (1) MXPA04007295A (en)
NO (1) NO337006B1 (en)
NZ (1) NZ534452A (en)
PL (1) PL211836B1 (en)
PT (2) PT2036549E (en)
RU (1) RU2301673C2 (en)
SE (1) SE0200312D0 (en)
SI (2) SI2036549T1 (en)
UA (1) UA79445C2 (en)
WO (1) WO2003063842A1 (en)
ZA (1) ZA200406086B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200312D0 (en) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
US9084799B2 (en) 2005-02-11 2015-07-21 Pulmagen Therapeutics (Synergy) Limited Inhaled combination therapy
SI1845994T1 (en) * 2005-02-11 2009-06-30 Argenta Discovery Ltd Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases
DE102006053374A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical formulation for aerosols with two or more active substances and at least one surface-active substance
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
GB0712454D0 (en) * 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
US20130160761A1 (en) * 2008-11-04 2013-06-27 Cipla Limited Pharmaceutical Aerosol Composition
NZ574666A (en) * 2009-02-05 2009-04-30 Nexus6 Ltd A medicament inhaler holder that uses optical means to count and display the number of doses used
JP5670421B2 (en) 2009-03-31 2015-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Component surface coating method
JP5763053B2 (en) 2009-05-18 2015-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Adapter, inhaler and atomizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
WO2011064163A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
JP5715640B2 (en) 2009-11-25 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Nebulizer
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
BR112013001119A2 (en) * 2010-07-16 2016-05-24 Cipla Ltd pharmaceutical composition, process for manufacturing a pharmaceutical composition, use of r (+) budesonide and a bronchodilator, and method of prophylaxis or treatment of a respiratory, inflammatory, or obstructive airway disease
CN106377503A (en) * 2010-08-03 2017-02-08 奇斯药制品公司 Pharmaceutical formulations comprising phosphodiesterase inhibitor
CA2812262A1 (en) * 2010-09-22 2012-03-29 Map Pharmaceuticals, Inc. Aerosol composition for administering drugs
US20120204871A1 (en) 2011-02-10 2012-08-16 Julio Cesar Vega Stable, non-corrosive formulations for pressurized metered dose inhalers
TWI399202B (en) * 2011-03-17 2013-06-21 Intech Biopharm Ltd The preparation for formulation composition and manufacturing processes of metered dose inhalers treated respiratory diseases
WO2012130757A1 (en) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medical device comprising a container
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
MY171271A (en) 2011-08-19 2019-10-07 Intech Biopharm Ltd Method for preparing metered dose sprayed inhaler for treating respiratory disease
WO2013152894A1 (en) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Atomiser with coding means
WO2015018904A1 (en) 2013-08-09 2015-02-12 Boehringer Ingelheim International Gmbh Nebulizer
EP2835146B1 (en) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Nebulizer
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201321712D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
PL3139979T3 (en) 2014-05-07 2023-12-27 Boehringer Ingelheim International Gmbh Unit, nebulizer and method
JP6745225B2 (en) 2014-05-07 2020-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Container, display device, and nebulizer
ES2874029T3 (en) 2014-05-07 2021-11-04 Boehringer Ingelheim Int Nebulizer
WO2016018892A1 (en) * 2014-07-29 2016-02-04 3M Innovative Properties Company Method of preparing a pharmaceutical composition
US11559505B2 (en) 2015-12-04 2023-01-24 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
CN106581010B (en) * 2016-12-28 2019-03-05 四川普锐特医药科技有限责任公司 A kind of aerosol preparation and metered dose inhalation aerosol
AU2018318123A1 (en) 2017-08-15 2020-03-19 Nephron Pharmaceuticals Corporation Aqueous nebulization composition
AU2019287541A1 (en) 2018-06-14 2021-01-21 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
JP7402631B2 (en) 2018-08-27 2023-12-21 帝人株式会社 Ultrafine carbon fiber mixture, manufacturing method thereof, and carbon-based conductive aid
CN109464429B (en) * 2018-12-13 2021-04-27 上海方予健康医药科技有限公司 Inhalation pressure quantitative aerosol pharmaceutical composition and preparation method thereof
CN112137957B (en) 2019-06-26 2022-07-29 长风药业股份有限公司 Medicinal inhalation aerosol and preparation method thereof
CN112972384B (en) * 2019-12-02 2022-03-18 长风药业股份有限公司 Preparation method of glycopyrronium bromide and indacaterol bulk drug micro-powder mixture

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6123924A (en) * 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
IL103238A (en) * 1991-09-25 1995-07-31 Fisons Plc Pressurised aerosol compositions
ATE213946T1 (en) 1991-12-18 2002-03-15 COMPOSITION CONTAINING FORMOTEROL AND BUDESONIDE
DE19536902A1 (en) * 1995-10-04 1997-04-10 Boehringer Ingelheim Int Miniature fluid pressure generating device
SE9603669D0 (en) 1996-10-08 1996-10-08 Astra Ab New combination
DK0938467T3 (en) * 1996-11-11 2002-10-07 Sepracor Inc Process for preparing optically pure isomers of formoterol
SE9703407D0 (en) * 1997-09-19 1997-09-19 Astra Ab New use
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
SE9802073D0 (en) * 1998-06-11 1998-06-11 Astra Ab New use
EP1100465B1 (en) 1998-07-24 2004-11-24 Jago Research Ag Medicinal aerosol formulations
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SE9900834D0 (en) 1999-03-09 1999-03-09 Astra Ab Novel combination
PE20011227A1 (en) 2000-04-17 2002-01-07 Chiesi Farma Spa PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS IN THE FORM OF HARD AGGLOMERATES
GB0009584D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0016876D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Novel formulation
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
SE0200312D0 (en) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition

Also Published As

Publication number Publication date
US20100275913A1 (en) 2010-11-04
US11311558B2 (en) 2022-04-26
BR0307193A (en) 2004-11-03
DE60332067D1 (en) 2010-05-20
PT2036549E (en) 2010-06-22
US8575137B2 (en) 2013-11-05
SI1474117T1 (en) 2009-06-30
KR100947168B1 (en) 2010-03-12
US20050089478A1 (en) 2005-04-28
CN1287774C (en) 2006-12-06
CA2474479A1 (en) 2003-08-07
CO5611098A2 (en) 2006-02-28
EP2036549A1 (en) 2009-03-18
RU2004122921A (en) 2005-06-10
MXPA04007295A (en) 2004-10-29
PL211836B1 (en) 2012-06-29
ZA200406086B (en) 2006-01-25
CY1110081T1 (en) 2015-01-14
AU2003206289B2 (en) 2007-09-06
PL372118A1 (en) 2005-07-11
KR20090125857A (en) 2009-12-07
EP1474117B1 (en) 2009-02-25
IS2960B (en) 2017-02-15
KR20040081757A (en) 2004-09-22
JP5259636B2 (en) 2013-08-07
IL163160A (en) 2013-12-31
SE0200312D0 (en) 2002-02-01
ES2321180T3 (en) 2009-06-03
SI2036549T1 (en) 2010-07-30
DK2036549T3 (en) 2010-07-12
ATE463241T1 (en) 2010-04-15
IS7360A (en) 2004-07-21
US20190216828A1 (en) 2019-07-18
EP1474117A1 (en) 2004-11-10
CA2474479C (en) 2011-04-05
ATE423552T1 (en) 2009-03-15
NO20043458L (en) 2004-08-19
ES2342509T3 (en) 2010-07-07
HK1126684A1 (en) 2009-09-11
IS9028A (en) 2013-04-16
WO2003063842A1 (en) 2003-08-07
RU2301673C2 (en) 2007-06-27
US10166247B2 (en) 2019-01-01
DE60326320D1 (en) 2009-04-09
US7759328B2 (en) 2010-07-20
DK1474117T3 (en) 2009-05-25
US20170368078A1 (en) 2017-12-28
WO2003063842A9 (en) 2004-04-22
PT1474117E (en) 2009-04-24
UA79445C2 (en) 2007-06-25
US20140286878A1 (en) 2014-09-25
NZ534452A (en) 2006-01-27
CN1625392A (en) 2005-06-08
US20120216802A1 (en) 2012-08-30
NO337006B1 (en) 2015-12-21
JP2010132695A (en) 2010-06-17
US8143239B2 (en) 2012-03-27
US20210069215A1 (en) 2021-03-11
EP2036549B1 (en) 2010-04-07
JP2005521663A (en) 2005-07-21
CY1109030T1 (en) 2014-07-02

Similar Documents

Publication Publication Date Title
US11311558B2 (en) Composition for inhalation
AU2003206289A1 (en) Composition for inhalation
US20170281529A1 (en) Formulations
Barben et al. Repeatability of bronchial responsiveness to mannitol dry powder in children with asthma
AU2013203244B2 (en) Improved formulations

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION